Original full paper

Multidrug therapy for muscular dystrophy in a GRMD (Golden Retriever muscular dystrophy) model

Renata A. Fernandes¹, Paula Fratini¹, José L. Nogueira¹, Dilayla K. Abreu¹, David Feder², Ana Claudia O. Carreira³, Maria A. Miglino¹

¹Department of Surgery, Faculty of the Veterinary Medicine and Animal Science, Universidade de São Paulo, São Paulo, Brazil.  
²School of Medicine ABC, Santo Andre, SP, Brazil.  
³Internal Medicine Department, School of Medicine and Institute of Chemistry, Universidade de São Paulo, São Paulo, SP, Brazil.  
*Corresponding author: Paula Fratini. Universidade de São Paulo (USP) – Faculdade de Medicina Veterinária e Zootecnia – Departamento de Cirurgia; Av. Prof. Dr. Orlando Marques de Paiva, 87, Cidade Universitária; São Paulo – SP – Brasil. CEP: 05508-270; Tel.: +55 11 3091 7690; Fax: +55 11 3091 7690; E-mail: fratini@usp.br

Submitted March 22nd 2016, Accepted August 22nd 2016

Abstract

Golden Retriever muscular dystrophy (GRMD) is a degenerative, progressive and lethal genetic disease, homologous to human Duchenne muscular dystrophy (DMD). For both there is no cure and clinical interventions are limited to treating clinical signs. As potential treatment, we did a pilot study in GRMD and administered a cocktail of frequently used drugs that might work synergistically. Biochemical blood values were investigated and histology and real-time PCR of muscle biopsies were performed. Significant improvements occurred in experimental Golden Retrievers dogs in regard to the levels of alanine aminotransferase, neutrophils, lymphocytes and CK, which began to show values closer to normal ones when compared to control animals, as well as moderate inflammatory infiltrates in the musculature, according to histology. The drug cocktail seemed to work systemically, but did not interfere with the gene defect, thus having potential value for maintaining the health status and preventing the progression of muscular dystrophy in GRMD model.

Key words: treatment, disease of dogs, muscle diseases, canine dystrophy.

Introduction

Duchenne muscular dystrophy (DMD) is a lethal human X chromosome genetic degenerative disease caused by a mutation in the gene encoding the protein dystrophin. Currently, clinical interventions are limited to treating symptoms and there is no cure. There are two common animal models, for this human disease, mdx mice and GRMD (Golden retriever muscular dystrophy) dogs. Although mdx mice are widely used, they show only minimal clinical signs and their lifespan is reduced only by 25% (7, 15). In contrast, GRMD dogs are regarded to better model the situation of human DMD, since the symptoms are much more severe than those in mdx mice. Thus, molecular, histological and clinical studies validated GRMD as an adequate model for understanding the course of human DMD (8, 9, 22). The severity of the dystrophy necessitates the search for drugs that ameliorate symptoms and improve quality of life (2). In particular available drugs with known toxicological profile (3) may be promising (12). As a potential treatment to slow down progression of the disease, we administered a combination of known drugs that could act synergistically. Seven drugs were selected: sildenafil, a drug with cardioprotective effect that may reduce the weakness of the diaphragm muscle and normalize the expression of TNF alpha (6, 18). Ursodeoxycholic acid which may inhibit the action of cytokine NF-kB, an important regulator of muscle regeneration (19); acetylcysteine which has antioxidant function and may also work in that regard; losartan...
potassium which is known for cardioprotective effects and decreased fibrosis in mdx mice (4); and mycophenolate mofetil which inhibits T and B lymphocytes responses in tissue inflammation. We aim to identify differences in experimentally treated affected dogs in contrast to controls without treatment with this cocktail.

Material and methods

Golden Retriever dogs with muscular dystrophy were identified during the neonatal period based on high levels of creatine kinase (CK) in blood tests and clinical signs of the disease (13). When the dogs were four weeks old, PCR genotyping was performed to confirm the clinical findings (10).

Animal experimentation was approved by the Ethics Committee for Animal Use of the School of Veterinary Medicine (CEUA), Universidade de São Paulo, São Paulo, Brazil, (FMVZ-USP) under protocol 1979/2010. The experimental treatments and the required care were administered by the colony veterinarians. The dogs were studied from two to ten months of age onwards.

Male Golden Retrievers with GRMD (n = 6) from the GRMD-Brazil colony were distributed into two groups: a control group (n = 2; dogs C1 and C2), which did not receive any treatment, and an experimental group (n = 4; Dogs E1, E2, E3 and E4), they received the following drugs daily: 5 mg/kg sildenafil (16), 10 mg/kg ursodeoxycholic acid, 40 mg/day acetylcysteine (20), 3.5 mg/kg losartan potassium (1), 10 mg/kg mycophenolate mofetil (12), 13 mg/kg thalidomide (11) and 1.5 mg/kg diltiazem. Blood eva

Total RNA was isolated from muscle tissues using TRIzol method according to the manufacturer’s instructions. cDNA synthesis and qRT-PCR assays were performed according to (11). The endogenous Canis familiaris GAPDH gene (AGTAGGTCTACCAGGCAAAA and CACACATACTCGACACAGCAT) was used for data normalization. The following primers were used to assess mRNA expression: dystrophin (TGAGGACGACCTTCTTCTC and ACCGGCCAAATGACTTGTCT), myostatin (CTAGACCCGGTCAGACTCC and AGGGATTCAGGCCCATCTTCT), utrophin (TTTGATGAATGCTCGGGA and CAAATTGGCTCTCTCCCTCA), TNFα (CTCTCGAACCCCAAGTGACAAG and ATCAGCTGTGTCTGTCTCA), TGF-β (AGTTAAGCAGGAGCCAGCATGTTG and GATCCTGCGGAAGTGCAATGAGAC) and VEGF (TTGCTGCTCTACCTCCACCAT and TGTGCTCTCCCTGGCATAG).

A dissociation cycle was performed after each run to check for non-specific amplification. All samples were tested in triplicate, and relative expression was calculated by the 2−ΔΔCP method (16).

Results

Histologically, muscles of experimental animals compared to the controls showed a slightly better organization of muscle fibers, reduction of inflammatory infiltrates and less deposition of connective tissue and necrosis (Fig. 1). Blood values resulted in significant decrease of leukocyte levels as well as CK (Table 1). The expression of the dystrophin, myostatin, utrophin, TGF-β, TGF-α and VEGF were evaluated by qRT-PCR, but did not show significant differences between experimental and control individuals (data not shown). Clinical changes were not observed in the dogs studied, only biochemical and moderate histological changes were detected.
Multidrug therapy for muscular dystrophy in a GRMD (Golden Retriever muscular dystrophy) model.


Figure 1. Muscle biopsy of the dogs. (A) Biceps femoralis muscle before treatment; there is disorganization of the fibers, perimysial presence of inflammatory infiltrates (black arrow), atrophic fibers (white arrow), fibers in phagocytosis (*). (B) Muscle from a treated dog; there is less perimysial infiltrates (black arrow), fewer atrophic fibers (white arrow), great amount of normal fibers (*), suggesting discrete improvement.

Table 1. Hematological and biochemical mean values of the control and experimental groups.

<table>
<thead>
<tr>
<th>Parameter (reference value)</th>
<th>Control group mean</th>
<th>Experimental group mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocytes (6-15 x 10^3/mm^3)</td>
<td>18.48 ± 1.43</td>
<td>13.97 ± 4.89</td>
</tr>
<tr>
<td>Lymphocytes (1.5-5 x 10^3/mm^3)</td>
<td>6.89 ± 1.3</td>
<td>4.97 ± 1.9</td>
</tr>
<tr>
<td>Hematocrit (37-54%)</td>
<td>36.5 ± 2.66</td>
<td>30 ± 8.17</td>
</tr>
<tr>
<td>Platelets (200-500 x 10^3)</td>
<td>675.83 ± 121.15</td>
<td>470.80 ± 196.18</td>
</tr>
<tr>
<td>Urea (up to 40 mg/dL)</td>
<td>28.23 ± 4.93</td>
<td>43.06 ± 15.91</td>
</tr>
<tr>
<td>Creatinine (up to 1.3 mg/dL)</td>
<td>0.53 ± 0.13</td>
<td>0.67 ± 0.2</td>
</tr>
<tr>
<td>ALT (up to 50 U/L)</td>
<td>325.9 ± 68.5</td>
<td>240 ± 80.72</td>
</tr>
<tr>
<td>Alkaline phosphatase (up to 130 U/L)</td>
<td>31.63 ± 11.12</td>
<td>31.06 ± 7.42</td>
</tr>
<tr>
<td>CK (20-200 U/L)</td>
<td>21.34 ± 8.30</td>
<td>11.56 ± 5.15</td>
</tr>
<tr>
<td>Albumin (2.5-4.5 g/dL)</td>
<td>3.03 ± 0.12</td>
<td>2.9 ± 0.13</td>
</tr>
<tr>
<td>Total protein (5.5-8.0 g/dL)</td>
<td>6.1 ± 0.21</td>
<td>6.1 ± 0.51</td>
</tr>
</tbody>
</table>

Discussion

The drug cocktail seemed to work on a systemic level. Blood values showed that our treatment decreased inflammatory processes by inhibiting the lymphocyte response that is controlled by the pro-inflammatory cytokine TNF alpha. A similar reaction occurred in mdx mice treated with sildenafil only (6, 18). Thus, these drugs may contribute to arrest degenerative processes in dystrophic muscles. Boys suffering from DMD have high ALT values, but without the generally associated hepatic symptoms, indicating that muscular diseases also increase this marker (17). Thus, the decline of ALT in our experimental dogs indicated an improvement of the health status. Likewise this could be assumed for the observed increase of CK, because this enzyme is always highly expressed in muscular diseases and contributed to the diagnosis of muscular lesions (5). We supposed that especially acetylcisteine may be effective in reducing CK values and associated muscular lesions; similar to what is known for mdx mice treated with that drug (21). The above-mentioned improvements were supported by histological findings in our experimental animals that presented slight improvement in their musculature when...
compared to controls, although it was not associated with clinical improvement. The relative similar expression of genes relevant for muscular dystrophy indicated that the drug cocktail did not interfere with the gene defect. Nevertheless, our pilot study suggests promising effects on improving animal health status and probably also on arresting the lethal phase of the disease, and thus further, clinically relevant studies seems to be promising.

Acknowledgements

We warmly thank our guest professor at USP, Andrea Mess, for helpful comments on a former version of this manuscript.

References


20. TEO SK., EVANS MG., BROCKMAN MJ., EHRHART J., MORGAN JM., STIRLING DI.,
